$3995 | Single User
$7990 | Site License
$11985 | Enterprise License

EpiCast Report: Vasculitis - Epidemiology Forecast to 2024

Published by Global Data: 01 Jan 2016 | 18078 | In Stock

Introduction

EpiCast Report: Vasculitis - Epidemiology Forecast to 2024

Summary

Vasculitis is a group of heterogeneous disorders affecting persons of both sexes and all ages. These disorders are characterized by inflammation and necrosis of the blood vessels including the veins, arteries, and capillaries. There are various forms of vasculitis, and their clinical expressions may differ greatly in terms of symptoms observed, severity and duration of the disease depending on disease site and type of blood vessels involved.

Due to the lack of a uniformly accepted classification criteria for vasculitis, GlobalData epidemiologists obtained data for each vasculitis disorder from studies that categorized patients with vasculitis with the Chapel Hill Consensus Conference (CHCC) definitions, the 2012 revised CHCC definitions, the 1990 ACR definitions for select vasculitis disorders, the European Medicines Agency (EMA) algorithm, or by clinical diagnosis. Studies using the Hammersmith criteria, the Japanese Diagnostic Criteria, and the International Study Group Criteria were also included for eGPA, TA, and BD, respectively. This approach was taken by GlobalData epidemiologists in order to utilize data from the most pertinent and up-to-date studies on vasculitis in the forecast without missing potentially important studies.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of vasculitis (includes AAV, LVV, BD, and KD) for ages 15 and older will increase from 82,019 diagnosed incident cases in 2014 to 95,428 diagnosed incident cases in 2024, at an Annual Growth Rate (AGR) of 1.63% during the forecast period. GlobalData epidemiologists forecast that the diagnosed prevalent cases of selected vasculitis disorders (includes AAV, TA, and BD) for ages 15 years and older will increase from 137,603 diagnosed prevalent cases in 2014 to 145,229 diagnosed prevalent cases in 2024, at an AGR of 0.55% during the forecast period. GlobalData epidemiologists forecast that in 2024, the 5EU (France, Germany, Italy, Spain, and UK) will have the highest number of diagnosed incident and diagnosed prevalent cases, with 31,916 diagnosed incident cases and 58,073 diagnosed prevalent cases, accounting for 42% and 40% of the diagnosed incident and diagnosed prevalent cases in the 7MM, respectively.

Scope

- The Vasculitis EpiCast Report provides an overview of the risk factors and global trends of selected vasculitis disorders in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The selected vasculitis disorders are anti-neutrophil cytoplasmic antibod-associated vasculitis (AAV) (microscopic polyangitis [MPA], granulomatosis with polyangitis [GPA], and eosinophilic granulomatosis with polyangitis [eGPA]), large vessel vasculitis (LVV) (giant cell arteritis [GCA] and Takayasu's arteritis [TA]), Behҫet’s disease (BD), and Kawasaki disease (KD). The report includes a 10-year epidemiological forecast for the diagnosed incident cases of AAV, LVV, BD, and KD, as well as the diagnosed prevalent cases of AAV, TA, and BD. Age and sex segmentations are also provided.

- The vasculitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Vasculitis EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global vasculitis market.

- Quantify patient populations in the global vasculitis market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for vasculitis therapeutics in each of the markets covered.

Table of Contents
for EpiCast Report: Vasculitis - Epidemiology Forecast to 2024

  • 1 Table of Contents

    1 Table of Contents 4

    1.1 List of Tables 6

    1.2 List of Figures 7

    2 Introduction 8

    2.1 Catalyst 8

    2.2 Related Reports 9

    2.3 Upcoming Reports 10

    3 Epidemiology 11

    3.1 Disease Background 11

    3.2 Risk Factors and Comorbidities 12

    3.3 Global Trends 14

    3.4 Forecast Methodology 16

    3.4.1 Sources Used 18

    3.4.2 Sources Not Used 38

    3.4.3 Forecast Assumptions and Methods 38

    3.5 Epidemiological Forecast for Vasculitis, 2014-2024 63

    3.5.1 Diagnosed Incident Cases of AAV 63

    3.5.2 Diagnosed Prevalent Cases of AAV 65

    3.5.3 Age-Standardized Incidence of AAV 66

    3.5.4 Diagnosed Incident Cases of LVV - TA and GCA 70

    3.5.5 Diagnosed Prevalent Cases of TA 72

    3.5.6 Age-Standardized Incidence of LVV 74

    3.5.7 Diagnosed Incident Cases of BD 76

    3.5.8 Diagnosed Prevalent Cases of BD 78

    3.5.9 Age-Standardized Incidence of BD 80

    3.5.10 Diagnosed Incident Cases of KD 81

    3.6 Discussion 82

    3.6.1 Epidemiological Forecast Insight 82

    3.6.2 Limitations of the Analysis 83

    3.6.3 Strengths of the Analysis 85

    4 Appendix 86

    4.1 Bibliography 86

    4.2 About the Authors 93

    4.2.1 Epidemiologists 93

    4.2.2 Reviewers 94

    4.2.3 Global Director of Therapy Analysis and Epidemiology 95

    4.2.4 Global Head of Healthcare 95

    4.3 About GlobalData 96

    4.4 About EpiCast 96

    4.5 Disclaimer 97

List Of Tables
in EpiCast Report: Vasculitis - Epidemiology Forecast to 2024

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Vasculitis 13

Table 2: 2012 Revised CHCC Definitions of Vasculitides 17

Table 3: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of MPA 18

Table 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MPA 19

Table 5: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GPA 20

Table 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of GPA 21

Table 7: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of eGPA 22

Table 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of eGPA 23

Table 9: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GCA 24

Table 10: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of TA 25

Table 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of TA 26

Table 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of BD 27

Table 13: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of BD 28

Table 14: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of KD 29

Table 15: 7MM, Sources Not Used in Epidemiological Analysis of AAV, LVV, BD, and KD 38

Table 16: 7MM, Diagnosed Incident Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024 63

Table 17: 7MM, Diagnosed Prevalent Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024 65

Table 18: 7MM, Diagnosed Incident Cases of LVV, Ages ≥15 Years, Both Sexes, N, 2014-2024 70

Table 19: 7MM, Diagnosed Prevalent Cases of TA, Ages ≥15 Years, Both Sexes, N, 2014-2024 72

Table 20: 7MM, Diagnosed Incident Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024 76

Table 21: 7MM, Diagnosed Prevalent Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024 78

Table 22: 7MM, Diagnosed Incident Cases of KD, Ages ≤5 Years, Both Sexes, N, 2014-2024 81

List Of Figures, Charts and Diagrams
in EpiCast Report: Vasculitis - Epidemiology Forecast to 2024

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024 64

Figure 2: 7MM, Diagnosed Prevalent Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024 66

Figure 3: 7MM, Age-Standardized Diagnosed Incidence of MPA, Ages ≥15 Years, Both Sexes, N, 2014 67

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of GPA, Ages ≥15 Years, Both Sexes, N, 2014 68

Figure 5: 7MM, Age-Standardized Incidence of eGPA, Ages ≥15 Years, Both Sexes, N, 2014 69

Figure 6: 7MM, Diagnosed Incident Cases of LVV, Ages ≥15 Years, Both Sexes, N, 2014-2024 71

Figure 7: 7MM, Diagnosed Prevalent Cases of TA, Ages ≥15 Years, Both Sexes, N, 2014-2024 73

Figure 8: 7MM, Age-Standardized Diagnosed Incidence of GCA, Ages ≥15 Years, Both Sexes, N, 2014 74

Figure 9: 7MM, Age-Standardized Diagnosed Incidence of TA, Ages ≥15 Years, Both Sexes, N, 2014 75

Figure 10: 7MM, Diagnosed Incident Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024 77

Figure 11: 7MM, Diagnosed Prevalent Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024 79

Figure 12: 7MM, Age-Standardized Incidence of BD, Ages ≥15 Years, Both Sexes, N, 2014 80

Figure 13: 7MM, Diagnosed Incident Cases of KD, Ages ≤5 Years, Both Sexes, N, 2014-2024 82

Additional Details

Publisher

Global Data

Publisher Information

Reference

18078 | GDHCER110-15

Number of Pages

98

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024SummaryNon-Hodgkin’s Lymphoma ...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024SummaryPulmonary Arte...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024SummarySmall Cell Lung Cancer ...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024SummaryThe Hepatitis B Virus (HBV...
24 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024SummaryRSV is a...
23 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024SummarySjögren’s syndrome (SS) is ...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024SummaryHuntington’s disease (HD)...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024SummarySystemic scle...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

EpiCast Report: Vasculitis - Epidemiology Forecast to 2024 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data